Jeito Capital leads a €132 million Series B funding round for Azafaros, a biopharma company targeting rare lysosomal storage disorders with its lead candidate, nizubaglustat.

Information on the Target

Jeito Capital, a prominent independent private equity firm specializing in the healthcare and biopharma sectors, has announced its leadership in an oversubscribed Series B funding round raising €132 million for Azafaros. Azafaros is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic options for patients suffering from rare lysosomal storage disorders. These treatments aim to slow or halt the progression of these conditions, which are characterized by genetic abnormalities and can result in severe neurodegeneration.

Founded in 2018, Azafaros emerged based on research from Leiden University and Amsterdam UMC. The company is spearheaded by a team of experts with extensive experience in developing and commercializing drugs for rare diseases. Azafaros is particularly advancing its lead candidate drug, nizubaglustat, which targets lysosomal storage disorders and has received orphan drug designation in both the United States and Europe, along with Fast Track status in the U.S. This positioning underscores the potential impact of their treatments in addressing significant unmet medical needs.

Industry Overview

The biopharmaceutical industry in France has seen notable advancements, particularly in the realm of rare diseases. Approximately 7,000 rare diseases are known globally, affecting millions of in